Germany $209 Billion Life Science Giant Merck Buys United States Biopharmaceutical Company SpringWorks Therapeutics for $3.9 Billion Representing +26% Premium to 20-Day Volume-Weighted Average Price of $37.38 (7/2/25) Prior to First Market Speculation of Potential Transaction, Merck Family is Largest Shareholder of Merck
29th April 2025 | Hong Kong
Germany life science Merck ($209 billion market value) has announced to buy United States biopharmaceutical company SpringWorks Therapeutics for $3.9 billion, representing +26% premium to 20-day volume-weighted average price of $37.38 (7/2/25) prior to first market speculation of potential transaction. SpringWorks Therapeutics – SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases and cancer. We developed and are commercializing OGSIVEO® (nirogacestat) as the first and only FDA-approved medicine for adults with desmoid tumors and GOMEKLI™ (mirdametinib) as the first and only FDA-approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN). We are also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Merck KGaA, Darmstadt, Germany – Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
“ Germany $209 Billion Life Science Giant Merck Buys United States Biopharmaceutical Company SpringWorks Therapeutics for $3.9 Billion Representing +26% Premium to 20-Day Volume-Weighted Average Price of $37.38 (7/2/25) Prior to First Market Speculation of Potential Transaction, Merck Family is Largest Shareholder of Merck “
Germany $209 Billion Life Science Giant Merck Buys United States Biopharmaceutical Company SpringWorks Therapeutics for $3.9 Billion Representing +26% Premium to 20-Day Volume-Weighted Average Price of $37.38 (7/2/25) Prior to First Market Speculation of Potential Transaction, Merck Family is Largest Shareholder of Merck
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2025 Investment Day
- March - Hong Kong
- March - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
